Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098420 · ClinicalTrials.gov registry record · Phase 2
Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03098420 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 29 participants.
The verdict
NCT03098420, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The study aims to improve the care of the obstetric population after cesarean section and improve total patient satisfaction by improving post-surgical pain control with the use of dexamethasone in combination with bilateral TAP blocks. The investigators will utilize a dose-escalation of dexamethasone in the TAP block to observe its effects at specific small doses. It is the hope of the investigator that the studied technique would become utilized routinely for the obstetric population following cesarean section. The investigators hope to show that the addition of dexamethasone in bilateral TAP blocks will prolong the duration of the block in a dose-dependent fashion. The investigators hope to improve post-operative pain following cesarean section, increase duration of TAP block with use of dexamethasone, decrease overall pain scores in the first 24-48 hours, and decrease opioid requirements after cesarean section. The primary endpoint will be estimation of duration of TAP block, being assessed within 48 hours after surgery. Secondary endpoints will include pain scores both in PACU and on the floor, average pain scores, time until first opioid administration, total opioid consumption in first 48 hours, use of PONV medications, and overall patient satisfaction.
Interventions
- DRUG Bupivacaine Hydrochloride
- DRUG Morphine
- DRUG 2mg Dexamethasone
- DRUG 4mg Dexamethasone
- DRUG Ropivacaine (TAP blocks)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03098420
The ClinicalTrials.gov registry entry for NCT03098420 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bupivacaine Hydrochloride is the first listed.
NCT03098420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03098420 about?
NCT03098420 is a clinical study titled "Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section". The study aims to improve the care of the obstetric population after cesarean section and improve total patient satisfaction by improving post-surgical pain control with the use of dexamethasone in combination with bilateral TAP blocks. The investigators will utilize a dose-escalation of dexamethaso...
What is the current status of trial NCT03098420?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-07. Estimated completion is 2021-05-20.
What interventions are being tested in trial NCT03098420?
The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), Morphine (DRUG), 2mg Dexamethasone (DRUG), 4mg Dexamethasone (DRUG), Ropivacaine (TAP blocks) (DRUG).
Who is sponsoring clinical trial NCT03098420?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.